Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study
| Autor: | Christine Klipping, Dietmar Trummer, Jan Endrikat, Susanne Parke, Marco Serrani, Ingrid Duijkers |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Ovulation medicine.medical_specialty Adolescent medicine.drug_class medicine.medical_treatment media_common.quotation_subject Endometrium chemistry.chemical_compound Internal medicine medicine Humans Nandrolone Progesterone media_common Estradiol Progestogen business.industry Ovary Estradiol valerate Obstetrics and Gynecology Luteinizing Hormone Contraceptives Oral Combined medicine.anatomical_structure Endocrinology Reproductive Medicine Dienogest chemistry Estrogen Pituitary Gland Cervix Mucus Female Follicle Stimulating Hormone Gonadotropin Luteinizing hormone business medicine.drug |
| Zdroj: | Contraception. 87:227-234 |
| ISSN: | 0010-7824 |
| DOI: | 10.1016/j.contraception.2012.07.008 |
| Popis: | Background The estrogen step-down/progestogen step-up 28-day estradiol valerate/dienogest (E 2 V/DNG) oral contraceptive effectively inhibits ovulation; however, limited data are available regarding its effects on estradiol (E 2 ), progesterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) or its additional extraovarian contraceptive effects. Study Design In this secondary analysis, 100 women received E 2 V 3 mg on days 1���2, E 2 V 2 mg/DNG 2 mg on days 3���7, E 2 V 2 mg/DNG 3 mg on days 8���24, E 2 V 1 mg on days 25���26 and placebo on days 27���28 for one treatment cycle. Measures included the presence/absence of cervical mucus; endometrial thickness; and serum E 2 , progesterone, and gonadotropin levels. Results E 2 , progesterone, LH and FSH levels did not exhibit the typical ovulatory increase and remained relatively stable during the cycle. E 2 V/DNG reduced mean maximal endometrial thickness and proportion of women with visible cervical mucus. All parameters returned to pretreatment levels during the posttreatment cycle. Conclusion E 2 V/DNG provides extraovarian contraceptive effects (reducing endometrial thickness and cervical mucus production) in addition to inhibiting ovulation, assuring contraceptive efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect